SHANGHAI, CHINA, Aug 25, 2023 – (ACN Newswire) – — First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. Since the launch of commercial sales at the end of October 2022 to June 30, 2023, HuaTangNing achieved a total sales revenue of RMB87.9 million…
Read More
